700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Case Report Open Access
Aim: We investigated the safety and feasibility of L-OHP with chronic renal failure (CRF) on hemodialysis (HD) patients by examining the influence of pharmacokinetics and pharmacodynamics of oxaliplatin (L-OHP). Furthermore, we investigated.
Methods: We present the results of three patients who were treated with modified FOLFOX6 (mFOLFOX6) chemotherapy for a mCRC with chronic renal failure on HD. We measured their plasma concentration of total platinum and free platinum. We evaluated whether L-OHP dose could be safely used for these patients. Different starting dose of L-OHP and 5-fluorouracil (50% and 75%) were used in these patients. Pharmacokinetics monitoring of platinum in plasma, plasma ultrafiltrates were measured these time schedule follow as: pre-chemotherapy infusion and 4 hours (pre-HD), 6 hours (half of HD), 8 hours (post HD), 48 hours after.
Results: The 50% of peak concentrations (Cmax) was 0.27 μgã»hr/mL ± 0.02 μg/mL and 75% Cmax was 0.41 μgã»hr/mL ± 0.02 μg/mL. 50% of the area under the concentration versus time curve (AUC) was 14.8 μgã»hr/mL ± 1.22 μgã»hr/mL and 75% AUC was 22.43 μgã»hr/mL ± 0.85 μgã»hr/mL.
Conclusion: We recognized these free plasma concentration which 50% dose of L-OHP was similar AUC between healthy and CRF patients. L-OHP pharmacokinetics and pharmacodynamics are altered in patients with CRF, but corresponding increase in L-OHP related hematological and non-hematological toxicities is not observed. It is important for cancer patients with CRF that the feasibility and efficacy of L-OHP combined chemotherapy should be determined.
Colorectal cancer, Chronic renal failure, Hemodialysis, Oxaliplatin, Bioactive Compound, Cellular Medicine, Epigenomics, Gene Therapy, Genetic Engineering in Medicine, Genomic Medicine, Human Molecular Genetics, Medicinal Biotechnology, Metabolomics, Molecular Basis of Cancer, Molecular Basis of Obesity, Molecular Diagnosis, Molecular Genetic Test, Molecular Medicine, Nuclear Medicine, Pathology and Molecular Medicine, Personalized Medicine